According to the National Rosacea Society, 16 million-plus Americans regularly deal with symptoms of rosacea. Flare-ups can feel like a nightmare: the patchy pink spots, the all-over facial redness, ...

Purvisha Patel, MD, is a board-certified dermatologist and founder of Advanced Dermatology & Skin Cancer Associates in Memphis and Visha Skincare. Deeptej Singh, MD, is a board-certified dermatologist ...

Please provide your email address to receive an email when new articles are posted on . More than 50% patients only try a rosacea treatment for 2 weeks despite the doctor-recommended 12 weeks.

Affecting up to 1 in 10 people worldwide, rosacea has a complex pathophysiology that remains inadequately understood, and research has hinted at multiple inflammatory and immune mediated processes ...

Do you feel like you’re always blushing or breaking out in pimples? You may have rosacea, a skin condition that affects more than 16 million Americans. Fortunately, doctors have tools to help. Other ...

Please provide your email address to receive an email when new articles are posted on . After three treatments, the effectiveness and excellent rates were 68.9% and 35.6%, respectively. Of the 16 ...

Journey Medical Corporation has announced the launch and initial distribution of Emrosi™, a new prescription medication designed to treat inflammatory lesions of rosacea in adults. Emrosi, which ...

While the exact cause of rosacea is unknown, those who have the condition know the acne-like condition can cause bumps and redness that appear on their faces, sometimes around their eyes and less ...

Even though rosacea is one of the most prevalent inflammatory skin diseases for which patients seek care in dermatology clinics, treatment options for the erythema and flushing associated with rosacea ...

FORT WORTH, Texas, Jan. 12 /PRNewswire/ -- Galderma Laboratories, L.P. today announced the availability of a new MetroGel(R) 1% Kit for the topical treatment of the inflammatory lesions of rosacea.

State Medicaid formularies demonstrate significant variability in rosacea treatment coverage, with only 10% of states offering unrestricted access to basic therapeutic options, in an analysis of ...